Catalyst Pharmaceuticals, Inc. Aktie News

CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members o...

Catalyst Pharmaceuticals, Inc. (CPRX) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript

Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

CORAL GABLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's...

Attributes 249% Revenue Growth to Portfolio Momentum and Focused Execution Attributes 249% Revenue Growth to Portfolio Momentum and Focused Execution

CORAL GABLES, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's...

Catalyst Pharmaceuticals, Inc. ( CPRX ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Michael Kalb - Executive VP, Treasurer & CFO Richard John Daly - President, CEO & Director Jeffrey Del Carmen - Executive VP & Chief Commercial Officer William Andrews - Chief Medical Officer Steven Miller - Executive VP, COO & Chief Scientific Officer Conference Call Participants Sam...

Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance to between $565 Million and $585 Million, Reflecting Better than Originally Forecasted Performance Recently Announced Share Repurchase Program of up to $200 Million, Signaling Confidence in Lon...